El interés en corto de GraniteShares Gold Trust Shares of Beneficial Interest da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de GraniteShares Gold Trust Shares of Beneficial Interest. Los datos de interés en corto se actualizan cada dos semanas.

GraniteShares Gold Trust Shares of Beneficial Interest (ARCA:BAR) Bolsa, Informe de interés en corto

Male,Hand,Holding,Gold,Ingot,And,Fluctuating,Gold,Price,Chart

Equities

Government

Market Summary

News

Specialty ETFs

Commodities

Economics

Federal Reserve

Markets

Analyst Ratings

ETFs

AAAU

FGDL

GLDM

IAUM

OUNZ

SGOL

El oro marca récords históricos mientras aumentan los temores económicos. ¿Qué provocó esta subida y qué puede venir?

Precios del oro alcanzan máximos históricos: cuánto podrías ganar con ETF estratégicos

GraniteShares Gold Trust Shares of Beneficial Interest

FC Barcelona Fan Token

BARK Inc

BARK, Inc. Redeemable Warrants, each whole warrant exercisable for shares of Common Stock at an exercise price of $11.50 per share

Baru Gold Corp

If approved by the FDA, Anaphylm would be the first and only orally delivered epinephrine option for the treatment of severe allergic reactions in the United States.

Biotech

Health Care

General

AQST

The FDA Has Accepts Aquestive Therapeutics' New Drug Application For Anaphylm For Type 1 Allergic Reactions, Including Anaphylaxis, With PDUFA Target Action Date Of January 31, 2026

Taoping Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOP#NASDAQ">TAOP</a>, the ", Company", ))), a provider of innovative smart cloud platform services and solutions, today announced that on June 13, 2025, it received notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming the Company has cured its bid price deficiency, and that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2). Accordingly, this matter is now closed and the Company's ordinary shares will continue to trade uninterrupted on Nasdaq under the ticker "TAOP".

TAOP

Taoping Regains Nasdaq Compliance, Stock To Trade Uninterrupted

On Friday, June 13, U.S. markets ended sharply lower as escalating Iran-Israel tensions rattled global markets. Oil prices jumped on fears of supply disruption, boosting energy and defense stocks, while airlines tumbled on rising fuel concerns.
Most sectors in the S&amp;P 500 declined, led by financials and tech. Despite positive consumer sentiment and stable inflation data, geopolitical risks weighed heavily on investor confidence and market performance.
According to economic data, the University of Michigan&#8217;s consumer sentiment index rose to 60.5 in June, up from 52.2 in the prior two months and above expectations of 53.5.
While most S&amp;P 500 sectors, including financials, tech, and materials, posted losses Friday, energy stocks closed higher against the trend. The Dow closed lower by 1.79% at 42,197.79, the S&amp;P 500 declined 1.13% to 5,976.97, and the Nasdaq slipped 1.30% to 19,406.83.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/macro-economic-events/25/06/45943707/us-economy-to-face-pretty-limited-impact-from-israel-iran-airstrikes-with-only-a-tiny-bit-recession-risk-say-economists" rel="noreferrer noopener">US Economy To Face &#8216;Pretty Limited&#8217; Impact From Israel-Iran Airstrikes, With Only A &#8216;Tiny Bit&#8217; Recession Risk, Say Economists</a>
<h2 class="wp-block-heading">Asia Markets Today</h2>
On Monday, Japan&#8217;s Nikkei 225 closed 1.29% higher at 38,324.00, led by gains in the Real Estate, Banking, and Textile sectors.
Australia&#8217;s S&amp;P/ASX 200 was up 0.01% at 8,548.40, led by gains in the Energy, IT and Telecoms Services sectors.
India&#8217;s Nifty 50 was up 0.89% at 24,937.40, and the Nifty 500 gained 0.79% to 23,086.95.
China&#8217;s Shanghai Composite was up 0.35% at 3,388.73, and Shanghai Shenzhen CSI 300 rose 0.25% to 3,873.80.
Hong Kong&#8217;s Hang Seng closed the session 0.70% higher at 24,060.9
<h2 class="wp-block-heading">Eurozone at 05:45 AM ET</h2>
The European STOXX 50 index was up 0.42%.
Germany&#8217;s DAX index gained 0.32%.
France&#8217;s CAC 40 rose 0.71%.
U.K.&#8217;s FTSE 100 index traded higher by 0.38%.
<h2 class="wp-block-heading">Commodities at 05:45 AM ET</h2>
Crude Oil WTI was trading lower by 0.60% at $70.86/bbl, and Brent was down 0.73% at $73.74/bbl.
Oil prices dipped Monday after a sharp surge on Friday, as Israeli-Iranian strikes over the weekend left oil facilities intact. Brent and WTI futures gave back earlier gains despite briefly rising over $4 in Asian trading.
Natural gas rose 2.90% to $3.685.
Gold traded lower by 0.61% to $3,431.70, Silver rose 0.10% to $36.393, and Copper fell 0.28% to $4.8008.
<h2 class="wp-block-heading">U.S. Futures</h2>
At 05:45 AM ET, the Dow Jones futures rose 0.36%, the S&amp;P 500 gained 0.41%, and Nasdaq 100 was up 0.49%.
<h2 class="wp-block-heading">Forex</h2>
At 05:45 AM ET, the U.S. Dollar Index declined 0.24% to 97.98, USD/JPY was up 0.01% to 144.12, and USD/AUD declined 0.42% to 1.5348.
The dollar held steady Monday amid Israel-Iran tensions and ahead of key central bank meetings, while risk currencies edged higher and oil prices eased from last week&#8217;s surge.
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia And Europe Markets Rise, Dollar Slips Ahead Of Central Bank Decisions - Global Markets Today While US Slept

Highlights:
<ul>
<li>Over $11 Million Raised:&nbsp;Proceeds were generated through the exercise of existing warrants. Chardan Capital Markets was the exclusive financial advisor in connection with public warrant exercises.</li>
<li>Update on NASDAQ Compliance:&nbsp;Klotho believes it now exceeds the stockholders' equity thresholds required to remain in compliance with NASDAQ listing requirements.</li>
<li>Zero Debt:&nbsp;Klotho has fully extinguished all outstanding debt, resulting in a debt-free balance sheet.</li>
</ul>
NEW YORK, June 16, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biogenetics company, today announced that over the course of the last ten days, it raised over $11 million in funding through the exercise of existing warrants by investors. The Company believes that it now surpasses Nasdaq's stockholders' equity requirement requirements outlined in its Nasdaq compliance plan.

KLTO

Klotho Neurosciences Raises Over $11M In Funding Through Exercise Of Existing Warrants By Investors

<ul>
<li>Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.</li>
<li>Strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE&#xAE; (zuranolone), and a novel CNS discovery platform.</li>
<li>Expected to be significantly accretive in 2026 with potential cost synergies of up to $200 million on an annual basis.</li>
<li>Upfront cash payment of $8.50 per share, plus one non-tradable contingent value right (CVR) payable upon achieving certain specific milestones collectively worth up to $3.50 per share in cash, for an aggregate of up to approximately $795 million or $12.00 per share.</li>
</ul>

SAGE

SUPN

Supernus Pharmaceuticals Agrees To Buy Sage Therapeutics For $8.50/Share Plus One Contingent Value Right Worth Up To $3.50 Per Share In Cash, For Total Consideration Of $12/Share

Coda Octopus Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODA#NASDAQ">CODA</a>) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.03 by 166.67 percent. This is a 38.46 percent decrease over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $7.02 million which beat the analyst consensus estimate of $4.46 million by 57.16 percent. This is a 31.82 percent increase over sales of $5.32 million the same period last year.

Earnings

Earnings Beats

CODA

Coda Octopus Group Q2 EPS $0.08 Beats $0.03 Estimate, Sales $7.02M Beat $4.46M Estimate

AIOT

PowerFleet Q4 Adj. EPS $0.02 Beats $(0.02) Estimate, Sales $103.64M Beat $103.59M Estimate

Powerfleet Expands Deployment Of Advanced AI Video Safety Solution With EverDriven Technologies

95.5% of patients with relapsed or refractory marginal zone lymphoma (MZL) treated with lisocabtagene maraleucel (liso-cel) achieved a response, with 62.1% achieving complete response and 88.6% maintaining a response at 24 months
New data show liso-cel demonstrated high rates of durable responses and a consistent safety profile in a fifth cancer type, the most of any CD19-directed CAR T cell therapy
Additional liso-cel data at ICML 2025 further reinforce BMS' commitment to unlocking the full potential of this therapy for patients
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com%2F&amp;esheet=54275367&amp;newsitemid=20250613870408&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=d665851409cd5753f968a6745c7e20f9">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) today announced the first disclosure of the primary analysis results of the marginal zone lymphoma (MZL) cohort of TRANSCEND FL, an open-label, global, multicenter, Phase 2, single-arm study evaluating Breyanzi (lisocabtagene maraleucel; liso-cel) in patients with relapsed or refractory disease. The new data will be presented at the 2025 International Conference on Malignant Lymphoma (ICML) in an oral presentation on June 19, building on <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.bms.com%2Fnews%2Fcorporate-financial%2F2025%2FBristol-Myers-Squibb-Announces-Positive-Topline-Results-for-Breyanzi-lisocabtagene-maraleucel-in-Adult-Patients-with-Relapsed-or-Refractory-Marginal-Zone-Lymphoma%2Fdefault.aspx&amp;esheet=54275367&amp;newsitemid=20250613870408&amp;lan=en-US&amp;anchor=positive+topline+results&amp;index=2&amp;md5=ab804680ec7fa20a8268604cd3793fbb">positive topline results</a> announced in February.

Bristol Myers Squibb Announces First Disclosure Of Primary Analysis Results Of MZL Cohort Of TRANSCEND FL, Phase 2, Single-Arm Study Evaluating Breyanzi In Patients With Relapsed Or Refractory Disease

The GEO Group, Inc. (NYSE:<a href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) ("GEO" or the "Company") announced today that its wholly-owned subsidiary, GEO Transport, Inc. has entered into a new five-year contract, inclusive of option periods, with the U.S. Marshals Service for the provision of secure transportation and contract detention officer services across three service regions covering 26 federal judicial districts and spanning 14 states.
The new contract is expected to generate up to approximately $147 million over the five-year period, or up to approximately $29 million in annualized revenues per full-year of operations, with margins consistent with GEO's Managed-Only services contracts which average approximately 15 percent.

Contracts

GEO Transport Secures 5-Yr Deal Valued At ~$147M With U.S. Marshals Service For Provision Of Secure Transportation And Contract Detention Officer Services

Needham analyst Laura Martin initiates coverage on MNTN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNTN#NYSE">MNTN</a>) with a Buy rating and announces Price Target of $25.

Price Target

Initiation

MNTN

Needham Initiates Coverage On MNTN with Buy Rating, Announces Price Target of $25

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

Ascendiant Capital analyst Edward Woo maintains Duos Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOT#NASDAQ">DUOT</a>) with a Buy and raises the price target from $9 to $11.

DUOT

Ascendiant Capital Maintains Buy on Duos Technologies Group, Raises Price Target to $11

<a href="https://www.globenewswire.com/Tracker?data=s1sqEipjS-Pbns36XpcoDIauzklQ8ObpOSSdPTUee-iIFIVy-B1UzKBnkS8NvKsGKA7M0Oi02cSnvC-lDW6cARKguAfgKol5WOXRHWzFncdeS5lNG9Cws4CcP5gOOUbJGxcotnNVOLs32_MW5gsbk_x6cu3CYSwAJZ5r-sQ3MruX2qLKYrI-aUnHHGrBzyWR2n9b1exWS4O3NSjrpNwo0i5QCz4X5ETpAKEzGx3pLfY=">Pharvaris</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHVS#NASDAQ">PHVS</a>), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced a summary of data that were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025.
"Pharvaris embraced the opportunity to engage in scientific exchange with the HAE thought leader community during EAACI as we presented data supporting the differentiated profile of deucrictibant for the prophylactic and on-demand treatment of bradykinin-mediated angioedema attacks," said Berndt Modig, Chief Executive Officer of Pharvaris. "Building on our R&amp;D call from last week, we shared data demonstrating the potential for deucrictibant to address the unmet needs of people living with bradykinin-mediated angioedema beyond HAE-1/2. Deucrictibant showed sustained attack reduction and improved quality of life measures in the randomized portion of the CHAPTER-1 study, which was maintained in the open-label extension study, as well as early-onset symptom relief and complete symptom resolution in a single dose in most attacks in our ongoing RAPIDe-2 on-demand long-term extension study. Finally, RAPIDe-3 is the first and only phase 3 on-demand study that will explore ‘end-of-progression' as a new pre-specified endpoint, which is particularly meaningful for people living with HAE. Together with the outcomes from other study endpoints, we will be able to assess the full impact of deucrictibant on an HAE attack from start to end."

PHVS

Pharvaris Shares New Data on Oral Treatment for Rare Swelling Disorder at Global Allergy Conference

A Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Model 3 was reportedly hit by a train after it got stuck on the railroad tracks while in FSD or Full Self-Driving mode.
What Happened: The driver, who was able to escape the car before it was hit by a train, said that the Tesla was in "self-driving mode", Electrek reported <a href="https://electrek.co/2025/06/16/tesla-on-self-driving-stuck-train-track-hit-train/">on </a>Monday.
The vehicle sustained minor damages, with the left mirror reportedly snapping off following the incident. Emergency services temporarily halted all rail operations to clear the vehicle with a crane, the report suggests.
Tesla did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment. 
Why It Matters: The incident follows Musk's claims that Tesla vehicles would be able to drive themselves to customers' houses straight from the factory after June 28. The comments were in line with a tentative <a href="https://www.benzinga.com/markets/tech/25/06/45876375/elon-musk-says-tesla-robotaxi-rides-begin-june-22-in-austin-full-self-driving-to-enable-home-delivery-by-june-28-were-being-super-paranoid">June 22 launch </a>for the EV giant's highly anticipated Robotaxi launch in Austin.
However, critics have raised concerns about the technology, with Gerber Kawasaki's CEO and Co-Founder, Ross Gerber, saying the technology needs a <a href="https://www.benzinga.com/markets/tech/25/06/45764059/ross-gerber-says-tesla-has-lot-of-work-to-do-on-fsd-ahead-of-robotaxi-launch-waymos-are-way-better">lot of work.</a>
Elsewhere, CEO Elon Musk's Cybercab ambitions also <a href="https://www.benzinga.com/markets/tech/25/06/45942936/elon-musks-cybercab-ambitions-just-got-a-boost-as-nhtsa-eases-regulations-for-autonomous-vehicles">got a major boost </a>as the National Highway Traffic Safety Administration, or NHTSA, announced a series of updates to regulations, making Autonomous vehicles exempt from some safety standards.
Tesla was also officially named as an AV operator in Austin by the local authorities, which led to Musk hailing the city a better option to launch the robotaxi than LA, where multiple Alphabet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) <a href="https://www.benzinga.com/markets/tech/25/06/45853688/tesla-robotaxi-rival-waymo-suspends-services-in-downtown-la-following-vandalism-during-anti-ice-protests">Waymo robotaxis were vandalized</a>.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="192" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16063525/tsla-June-16-2025-1-1024x192.jpg" alt="" class="wp-image-950528" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16063525/tsla-June-16-2025-1-1024x192.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16063525/tsla-June-16-2025-1-300x56.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16063525/tsla-June-16-2025-1-768x144.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16063525/tsla-June-16-2025-1-1536x288.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16063525/tsla-June-16-2025-1.jpg 1560w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Tesla scores well on Momentum, Quality and Growth metrics, but offers poor Value. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"> Benzinga Edge Stock Rankings</a> today!
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45943245/trump-says-he-was-amazed-that-tesla-ceo-elon-musk-endorsed-him-despite-his-anti-ev-stance">Trump Says He Was &#8216;Amazed&#8217; That Tesla CEO Elon Musk Endorsed Him Despite His Anti-EV Stance</a></li>
</ul>
Image vIa Shutterstock

GOOG

GOOGL

TSLA

Tesla Model 3 On FSD Mode Struck By Train After Getting Trapped On Railroad Tracks: Report

AIRS

AirSculpt Improves Capital Structure With $10M Debt Paydown Following Successful Stock Offering

Ascendiant Capital analyst Edward Woo maintains Surgepays (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SURG#NASDAQ">SURG</a>) with a Buy and raises the price target from $8.75 to $9.

SURG

Ascendiant Capital Maintains Buy on Surgepays, Raises Price Target to $9

Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock experienced a steep decline of approximately 40% in premarket trading on Monday following a sobering safety update for its <a href="https://www.benzinga.com/general/health-care">Duchenne muscular dystrophy (DMD)</a> gene therapy, Elevidys.
What Happened: On Sunday, Sarepta provided a safety update regarding Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy, and steps the company is taking to strengthen the safety profile in non-ambulatory patients.
These steps follow a second reported case of acute liver failure (ALF), <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45940036/sarepta-provides-safety-update-for-elevidys-and-initiates-steps-to-strengthen-safety-in-non-ambula" rel="noreferrer noopener">resulting in death</a>.
In March,&nbsp;Sarepta Therapeutics reported a patient death following treatment with Elevidys, having suffered <a target="_blank" href="https://www.benzinga.com/25/03/44376919/sarepta-therapeutics-reports-patient-death-post-elevidys-gene-therapy-treatment-stock-plunges" rel="noreferrer noopener">acute liver failure</a>.
The cases of ALF to date have both occurred in non-ambulatory (patients who cannot walk independently) individuals with Duchenne.
Sarepta and Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) temporarily halted several <a target="_blank" href="https://www.benzinga.com/25/04/44634689/sareptaroche-suspend-elevidys-gene-therapy-trials-in-europe-after-patient-death" rel="noreferrer noopener">clinical studies in April</a>.
During its first-quarter earnings release, Sarepta revised its 2025 total net product revenues guidance to $2.3-$2.6 billion <a target="_blank" href="https://www.benzinga.com/25/05/45261806/sarepta-therapeutics-stock-sinks-on-gloomy-forecast-analysts-cut-price-forecasts" rel="noreferrer noopener">from $2.9-$3.1 billion</a>.
William Blair writes that the revised guidance primarily concerns delayed Elevidys turnaround times.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45393806/ten-year-data-from-roches-breast-cancer-trial-shows-perjeta-based-regimen-cuts-death-risk-by-17" target="_blank" rel="noreferrer noopener">Ten-Year Data From Roche&#8217;s Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17%</a>
Key Safety Initiatives
As part of a comprehensive review of safety data, Sarepta is taking proactive steps to mitigate the risk of acute liver failure in non-ambulatory patients.
A panel will evaluate data and assess the company&#8217;s proposed regimen, which includes sirolimus and is supported by preclinical data demonstrating the effectiveness of additional immunosuppression in moderating liver enzyme elevations, a key factor in mitigating potential safety events.
Sarepta will share the panel&#8217;s recommendations with the U.S. Food &amp; Drug Administration (FDA), and implementation of any new regimen will be subject to FDA guidance and allowance.
In the meantime, Sarepta is temporarily suspending shipments of Elevidys for non-ambulatory patients.
For ambulatory patients, no treatment <a target="_blank" href="https://www.roche.com/investors/updates/inv-update-2025-06-15" rel="noreferrer noopener">changes</a> are being proposed and the current practice of administering corticosteroids before and after Elevidys infusion and post-treatment monitoring remains the same.
Sarepta has voluntarily paused dosing in the ENVISION clinical study (also known as Study SRP-9001-303).
ENVISION is a global, randomized, double-blind, placebo-controlled trial evaluating Elevidys in older ambulatory and non-ambulatory Duchenne muscular dystrophy patients.
In the U.S., it serves as the confirmatory trial required under the FDA&#8217;s accelerated approval pathway for non-ambulatory patients.
Price Action: SRPT stock is trading lower by 42.0% to $21.00 during the premarket session at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/biotech/25/06/45797348/early-wins-regenxbios-gene-therapy-helps-duchenne-patients-walk-stronger-longer" target="_blank" rel="noreferrer noopener">Early Wins: RegenXBio&#8217;s Gene Therapy Helps Duchenne Patients Walk Stronger, Longer</a></li>
</ul>
Photo via Shutterstock

Movers

RHHBY

SRPT

Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy

VEON Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>), a global digital operator ("VEON" or the "Company"), announces that it will shortly commence the third phase of its previously announced share buyback program with respect to the Company's American Depositary Shares ("ADSs"). This third phase of the buyback will be in the amount of up to USD 35 million.&nbsp;
The third phase of the share buyback program is being launched after the successful completion of the second phase on May 21, 2025. Cumulatively, the two earlier phases of the program have resulted in the repurchase of 1.43 million ADSs at an average repurchase price of USD 45.59 per ADS. VEON had announced a share buyback program of up to USD 100 million on August 1, 2024.&nbsp;
The Company continues to believe that its ADSs are undervalued relative to its operational performance and strategic potential. With the buyback program, VEON aims to optimize shareholder value and strengthen its financial position for future opportunities.&nbsp;
The buybacks will be conducted on the open market pursuant to a 10b5-1 plan signed with a registered broker-dealer, and in compliance with Rule 10b-18.
VEON is also considering options to raise external financing through a sub-benchmark &nbsp;private placement of bonds, with a tenor of up to approximately four years (the "Notes"), with the goal of supporting the Company's strategic initiatives and enhancing its financial flexibility. The Notes, if issued, will be issued by VEON Midco B.V. and guaranteed by VEON Amsterdam B.V. This evaluation is a part of VEON's ongoing capital planning effort and discussions with potential institutional investors are in progress.

Buybacks

VEON

VEON Launches $35M Buyback Phase as It Eyes Undervalued Shares and Boosts Shareholder Value

Follow on order will bring the airline's total commitment to 235 GTF-powered aircraft, including already delivered aircraft
PARIS, June 16, 2025 /PRNewswire/ -- Pratt &amp; Whitney, an RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) business, and Frontier Airlines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>) today announced the selection of Pratt &amp; Whitney GTF&#x2122; engines to power 91 Airbus A321neo aircraft, with the first of these aircraft currently scheduled for delivery in Q4 2026. Pratt &amp; Whitney will also provide Frontier Airlines with engine maintenance through a long-term EngineWise&#xAE; Comprehensive service agreement. This latest order will bring the airline's total commitment to 235 GTF-powered A320neo family aircraft, including already delivered aircraft.

Comments

GraniteShares Gold Trust Shares of Beneficial Interest

Interés en corto

GraniteShares Gold Trust Shares of Beneficial Interest (ARCA:BAR) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL